Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures

被引:75
作者
Meyer, T
Nindl, I
Schmook, T
Ulrich, C
Sterry, W
Stockfleth, E
机构
[1] Inst Immunol Clin Pathol & Mol Med, D-22339 Hamburg, Germany
[2] Univ Hosp Charite, Dept Dermatol, D-10117 Berlin, Germany
关键词
apoptosis; imiquimod; mode of action; TLR;
D O I
10.1046/j.0366-077X.2003.05632.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Toll-like receptor (TLR)-7 agonists represent a new group of immune response modifiers, which include imiquimod and resiquimod (R-848). Topically applied imiquimod is used for the treatment of both external and perianal genital warts, and benign and malignant epithelial lesions. Based on the induction of interferons and other cytokines in vitro and in vivo, regression of epithelial lesions probably depends on induction of both innate and cellular immune responses. As clinical remission is not always associated with inflammation, other mechanisms may also be involved. Using two different assays for detection of apoptosis (TUNEL test and gel analysis of DNA fragmentation), we observed induction of apoptosis by imiquimod in human epithelial cell lines (HeLa S3) and keratinocytes (HaCaT, A431 cells), as well as in mouse fibroblasts (McCoy cells). These findings suggest that the mode of action of imiquimod to eliminate virus-infected, dysplastic or neoplastic epithelial cells may also include the induction of apoptotic processes.
引用
收藏
页码:9 / 13
页数:5
相关论文
共 19 条
[11]   Imiquimod applied topically: a novel immune response modifier and new class of drug [J].
Miller, RL ;
Gerster, JF ;
Owens, ML ;
Slade, HB ;
Tomai, MA .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1999, 21 (01) :1-14
[12]  
Sambrook J., 2002, MOL CLONING LAB MANU
[13]   Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy [J].
Smith, KJ ;
Germain, M ;
Skelton, H .
DERMATOLOGIC SURGERY, 2001, 27 (06) :561-564
[14]  
STANLEY MA, 1999, PAPILLOMAVIRUS REP, V10, P23
[15]  
Stockfleth E, 2002, EUR J DERMATOL, V12, P569
[16]   A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses [J].
Stockfleth, E ;
Meyer, T ;
Benninghoff, B ;
Salasche, S ;
Papadopoulos, L ;
Ulrich, C ;
Christophers, E .
ARCHIVES OF DERMATOLOGY, 2002, 138 (11) :1498-1502
[17]   A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod [J].
Tyring, SK ;
Arany, I ;
Stanley, MA ;
Tomai, MA ;
Miller, RL ;
Smith, MH ;
McDermott, DJ ;
Slade, HB .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (02) :551-555
[18]   Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod [J].
Wagner, TL ;
Ahonen, CL ;
Couture, AM ;
Gibson, SJ ;
Miller, RL ;
Smith, RM ;
Reiter, MJ ;
Vasilakos, JP ;
Tomai, MA .
CELLULAR IMMUNOLOGY, 1999, 191 (01) :10-19
[19]  
Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554